KVUE Stock Analysis — Kenvue
Sector: Consumer staples
AI Verdict
KVUE trades at 15.0x next year's earnings while analysts expect a huge profit jump—cheap for the growth on offer if its brand moat holds, but the overbought RSI means the entry point is risky right now.
Competitive Moat
Kenvue owns household personal care brands like Tylenol, Listerine, and Band-Aid, giving it shelf space dominance and habitual consumer purchase patterns. Its moat is built on brand recognition and distribution agreements with major retailers, making it difficult for new entrants to displace its products.
Summary
Kenvue is trading at a sharp discount to its own history as the market waits for a big rebound in earnings.
Where It Stands
KVUE is up against a 1-year return of -8.72%, trades at 15.0x forward earnings (below the consumer staples median of 20x), and shows an RSI of 73.3, signaling overbought territory despite recent underperformance.
Key Metrics
- RSI: 73.3 — Overbought
- Trailing P/E: 23.1x
- Forward P/E: 15.0x
- PEG Ratio: 0.43
- Earnings Growth: +0.5%
- Revenue Growth: -0.0%
- Market Cap: $37.4B
- Dividend Yield: 0.04%
- 1-Year Return: -8.72%
- 52-Week High: $22.87
- 52-Week Low: $14.02
Analyst Consensus
6 Buy · 14 Hold · 0 Sell (20 analysts)
Bull Case
With forward EPS growth expected at 53.8% and a forward P/E of 15.0x, you're paying a low price for a big earnings rebound if management delivers.
Bear Case
The RSI at 73.3 means the stock is technically overbought, so a pullback to a neutral RSI could mean a 10%+ drop even if fundamentals don't change.
Catalyst to Watch
Watch for the next earnings report to confirm whether the forecasted 53.8% EPS growth is materializing.